Paper Details

  1. Home
  2. Paper Details

Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.

Author: BrainardDiana M, DoehleBrian, DoreGregory J, FlammSteven L, GaneEdward J, HanLingling, KumarSonal, McHutchisonJohn G, McNallyJohn, MogalianErik, PiankoStephen, RabinovitzMordechai, ReddyK Rajender, RobertsStuart K, ShiffmanMitchell L, StedmanCatherine A M, StrasserSimone I, TownerWilliam J

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Sofosbuvir plus velpatasvir (100mg) was well-tolerated and highly effective in treatment-experienced patients with genotype 1 or 3 HCV infection, achieving sustained virologic response rates of 96% or higher in most cohorts.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Effective treatment options are needed for patients with genotype 1 or 3 hepatitis C virus (HCV) infection in whom previous therapy has failed. OBJECTIVE: To assess the efficacy and safety of sofosbuvir plus velpatasvir, with and without ribavirin, in treatment-experienced patients. DE...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.7326/M15-1014

データ提供：米国国立医学図書館（NLM）

Sofosbuvir Plus Velpatasvir: A Powerful Combination for Hepatitis C Treatment

This research delves into the challenging world of hepatitis C virus (HCV) infection, exploring new treatment options for patients who have failed previous therapies. Imagine a desert landscape, where the relentless heat and arid conditions represent the persistent threat of HCV infection. This study investigates the efficacy and safety of sofosbuvir plus velpatasvir, a potent combination therapy, in treatment-experienced patients with genotype 1 or 3 HCV infection. It's like discovering a new oasis with a powerful antidote to a persistent disease.

Sofosbuvir Plus Velpatasvir: A Highly Effective Treatment for Hepatitis C

The study reveals that sofosbuvir plus velpatasvir, with or without ribavirin, is highly effective in achieving sustained virologic response (SVR12) in treatment-experienced patients with genotype 1 or 3 HCV infection. It's like finding a wellspring of healing, offering a sustained reprieve from the challenges of HCV infection. The results demonstrate the promise of this combination therapy as a valuable tool for combating this persistent disease.

Combating Hepatitis C: Seeking Effective and Sustainable Treatments

This study underscores the importance of developing effective and sustainable treatments for hepatitis C, particularly for patients who have failed previous therapies. It highlights the potential of sofosbuvir plus velpatasvir as a promising option for achieving sustained virologic response. Remember, just as a camel adapts to the changing conditions of the desert, healthcare providers need to adapt their treatment strategies to combat the ever-evolving challenges of viral infections.

Dr.Camel's Conclusion

This study offers a beacon of hope for patients with genotype 1 or 3 HCV infection who have struggled with previous therapies. It demonstrates the remarkable efficacy of sofosbuvir plus velpatasvir in achieving sustained virologic response, offering a new path toward a healthier future for individuals battling this debilitating disease.
Date :
  1. Date Completed 2016-04-07
  2. Date Revised 2017-11-16
Further Info :

Pubmed ID

26551263

DOI: Digital Object Identifier

10.7326/M15-1014

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.